Rubrik: europharm
(Treffer aus pharmind, Nr. 12, Seite 1941 (2013))
Waimer F | Stekly G | Torres Londo##241;o P | Niebert R | Steinhoff B
The Nagoya Protocol / Proposal for a Best Practice Guide on the implementation of the Nagoya Protocol · Waimer F, Stekly G, Torres Londo##241;o P, Niebert R, Steinhoff B ·
1 Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe und
2 SALUS Haus Gmbh & Co, KG, Bruckmühl und
3 Kräuter Mix GmbH, Abtswind und
4 Rheinische Friedrich-Wilhelms-Universität, Bonn und
5 Bundesverband der Arzneimittel-Hersteller e. V., Bonn
The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization to the Convention on Biological Diversity establishes a reliable framework on how researchers and companies will in the future obtain access to genetic resources 1) and to traditional knowledge associated with genetic resources for research and development. It intends to commit users of genetic material to respect national regulatory frameworks and customary rights of local communities and indigenous people over their traditional knowledge and genetic resources to ensure equitable benefit sharing in return for the use of genetic resources. ...